Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Aug 19, 2040formulationUS 11649259
Aug 7, 2036method-of-use (U-4358)US 10471087

FDA exclusivities (1)

Nov 3, 2030NCENew Chemical Entity (5y)4.2y

News(0)

no news has mentioned this drug yet

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

(doxecitine + doxribtimine)

Marketedupdated 3mo ago

by UCB SA

Approved

community read0 votes

🐶 often sniffed alongside

top 3

all catalysts(1)

approval · 1

Nov 3, 2025

approval

9mo ago

KYGEVVI (DOXECITINE) — FDA approval

(doxecitine + doxribtimine)

→

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 3, 2030

~4.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Aug 19, 2040formulationUS 11649259
Aug 7, 2036method-of-use (U-4358)US 10471087

FDA exclusivities (1)

Nov 3, 2030NCENew Chemical Entity (5y)4.2y

News(0)

no news has mentioned this drug yet

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

(doxecitine + doxribtimine)

🐶 often sniffed alongside

all catalysts(1)

Patent cliff

patents (2)

FDA exclusivities (1)

News(0)

Report a data issue

comments(0)

(doxecitine + doxribtimine)

🐶 often sniffed alongside

all catalysts(1)

Patent cliff

patents (2)

FDA exclusivities (1)

News(0)

Report a data issue

comments(0)